{"id":"W3110945690","doi":"10.1136/ijgc-2020-esgo.147","title":"518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers","year":2020,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Clovis Oncology; Amgen; Pfizer; PharmaMar; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Endometrial cancer; Oncology; Internal medicine; Cervical cancer; Durvalumab; Ovarian cancer; Tolerability; Cancer; Adverse effect; Clinical endpoint; Immunotherapy; Nivolumab; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064654,0.0009389758,0.001436747,0.0002519339,0.0002748721,0.0007143183,0.0005915742,0.00079518,0.004835051],"category_scores_gemma":[0.0006273091,0.00046567,0.001005835,0.0002263675,0.0006080023,0.0005764274,0.0002086027,0.002299566,0.001375324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008416361,"about_ca_system_score_gemma":0.0008424685,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001142828,"about_ca_topic_score_gemma":0.003575896,"domain_scores_codex":[0.9997874,0.00007954307,0.000009820568,0.00004249205,0.00002216145,0.00005868098],"domain_scores_gemma":[0.9997557,0.00004987023,0.00003738201,0.00002762967,0.00001298125,0.0001163828],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8012778,0.01395097,0.004098375,0.0006425783,0.001968121,0.0002116447,0.0001464754,0.00216613,0.03875035,0.000503781,0.008531899,0.1277519],"study_design_scores_gemma":[0.8571779,0.1190192,0.012601,0.00003592488,0.0006854345,0.0003771884,0.00004414671,0.00195814,0.003463716,0.0003144631,0.004285991,0.00003695165],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908541,0.002598347,0.0004324427,0.000743171,0.0001989566,0.0006396775,0.001224752,0.0001630689,0.003145537],"genre_scores_gemma":[0.9882399,0.001676859,0.001416121,0.0008754939,0.0001322885,0.00061042,0.002932624,0.00003766344,0.004078581],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004835051,"threshold_uncertainty_score":0.01617479,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02991415229694643,"score_gpt":0.318273490441432,"score_spread":0.2883593381444856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}